knowledge -WSS

knowledge

author：focus 2025-09-28 12:08:42 - browse：63198

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： The future of health care in the House

WSS

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Antibody drugs appear effective. Now can we make enough of them?

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

After half a century, Israel moves to evict squatter from his cave home on the beach

Companies helping big Covid

Sickle cell gene therapy cures need to be accessible in Africa

Wikipedia

knowledge

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Superbugs, antibiotic resistance get scrutiny in congress

United colonoscopy coverage change 'may cost lives,' doctors say

France's anti

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

3 questions for the future of Biden's cancer moonshot

How one medical school became remarkably diverse

Senate panel eyes new effort on drug shortages

Medical records are filled with copy

The future of health care in the House

leisure time

Stroke deaths set to near 10 million globally by 2050

EU fines Illumina $475 million over Grail acquisition

Grail's uphill battle for Medicare to cover its cancer screening test

VC firm General Catalyst wants to buy a health system

Sana to lay off nearly a third of staff, de

France's anti

entertainment

focus

hotspot

leisure time